BriaCell Therapeutics Corp.
BCT.TO
TSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.44M | 6.52M | 6.65M | 8.07M | 8.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.32M | 29.98M | 33.33M | 35.27M | 31.72M |
| Operating Income | -27.32M | -29.98M | -33.33M | -35.27M | -31.72M |
| Income Before Tax | -11.72M | -16.72M | -4.93M | -6.10M | -12.69M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.72 | -16.72 | -4.93 | -6.10 | -12.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 131.60K | 124.50K | 140.10K | 105.50K | 82.00K |
| Net Income | -11.59M | -16.60M | -4.79M | -6.00M | -12.61M |
| EBIT | -27.32M | -29.98M | -33.33M | -35.27M | -31.72M |
| EBITDA | -27.19M | -29.87M | -33.25M | -35.25M | -31.70M |
| EPS Basic | -5.01 | -13.28 | -4.38 | -5.64 | -11.98 |
| Normalized Basic EPS | -3.10 | -8.26 | -2.69 | -3.49 | -7.46 |
| EPS Diluted | -5.09 | -13.36 | -17.51 | -18.75 | -25.16 |
| Normalized Diluted EPS | -3.10 | -8.26 | -2.83 | -3.63 | -7.60 |
| Average Basic Shares Outstanding | 6.73M | 5.10M | 4.39M | 4.26M | 4.23M |
| Average Diluted Shares Outstanding | 6.73M | 5.10M | 4.43M | 4.30M | 4.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |